癌症中的HOTAIR:诊断,预后和治疗视角
Majid Nazari1, Emad Babakhanzadeh2, Arghavan Mollazadeh3
1Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, P.O. Box 64155-65117, Tehran, Yazd, Iran. Vision.nazari@gmail.com.
Cancer cell international
|December 20, 2024
概括
长非编码RNAHOTAIR在许多癌症中过度表达,促进瘤生长和抵抗力. 霍泰尔显示了早期癌症检测,结果预测和指导治疗选择的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 长非编码RNAHOTAIR在各种人类癌症中经常过度表达.
- 霍泰尔有助于癌症的进展,包括增强的扩散,迁移和治疗耐药性.
研究的目的:
- 对人类癌症中HOTAIR的研究进行全面审查.
- 要总结HOTAIR的分子机制,临床意义和治疗应用.
主要方法:
- 关于HOTAIR在癌症中的研究的文献综述.
- 分子机制和临床相关性的分析.
- 讨论涉及HOTAIR的治疗策略.
主要成果:
- 霍泰尔过度表达与瘤阶段,转移和生存相关.
- 霍泰尔与细胞增殖,迁移和对癌症治疗的抵抗有关.
- 霍泰尔作为早期检测和预后的潜在生物标志物.
结论:
- 霍泰尔是癌症发展和进展的重要因素.
- 作为瘤学中的生物标志物和治疗点,HOTAIR具有前景.
- 对HOTAIR应用的进一步研究可能会促进癌症诊断和治疗.
更多相关视频
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
10.3K
09:01Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
288
相关概念视频
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Tumor Immunotherapy
475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
